Barinthus Biotherapeutics Completes 1-for-13 Reverse Stock Split

TL;DR

**Barinthus Biotherapeutics just did a 1-for-13 reverse stock split, fewer shares, higher price per share.**

AI Summary

Barinthus Biotherapeutics plc filed an 8-K on January 5, 2024, to announce the completion of its previously disclosed reverse stock split. This means that for every 13 ordinary shares, shareholders now own 1 ordinary share, and for every 13 American Depositary Shares (ADSs), shareholders now own 1 ADS. This matters to investors because it significantly reduces the number of outstanding shares and ADSs, which typically aims to increase the per-share price and meet exchange listing requirements, potentially making the stock more attractive to institutional investors.

Why It Matters

This reverse stock split aims to boost the company's share price and maintain its listing on a major exchange, which could improve investor perception and liquidity.

Risk Assessment

Risk Level: medium — While a reverse stock split can increase share price, it doesn't change the company's underlying value or business fundamentals, and the stock price may still decline.

Analyst Insight

A smart investor would monitor the stock's performance in the coming weeks to see if the reverse split successfully boosts the share price and improves market perception, but also research the company's underlying business fundamentals as the split itself doesn't change them.

Key Numbers

• 1-for-13 — Reverse Stock Split Ratio (The ratio by which ordinary shares and American Depositary Shares were consolidated.)

Key Players & Entities

• Barinthus Biotherapeutics plc (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of the earliest event reported and filing date
• 13 (dollar_amount) — the ratio for the reverse stock split (1-for-13)

Forward-Looking Statements

• The per-share price of Barinthus Biotherapeutics plc's stock will increase post-split. (Barinthus Biotherapeutics plc) — high confidence, target: Q1 2024
• The company will maintain its listing on its current stock exchange. (Barinthus Biotherapeutics plc) — high confidence, target: Q2 2024

FAQ

Key Financial Figures

• $142 million — and cash equivalents are expected to be $142 million as of December 31, 2023. The prelimina

Filing Documents

• tm242118d1_8k.htm (8-K) — 32KB
• tm242118d1_ex99-1.htm (EX-99.1) — 21KB
• tm242118d1_ex99-1img001.jpg (GRAPHIC) — 16KB
• tm242118d1_ex99-1img002.jpg (GRAPHIC) — 26KB
• tm242118d1_ex99-1img004.jpg (GRAPHIC) — 40KB
• 0001104659-24-001799.txt ( ) — 393KB
• brns-20240105.xsd (EX-101.SCH) — 3KB
• brns-20240105_def.xml (EX-101.DEF) — 26KB
• brns-20240105_lab.xml (EX-101.LAB) — 36KB
• brns-20240105_pre.xml (EX-101.PRE) — 25KB
• tm242118d1_8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 5, 2024, Barinthus Biotherapeutics plc (the "Company") released the following preliminary information about its cash and cash equivalents as of December 31, 2023. The Company's preliminary estimated cash and cash equivalents are expected to be $142 million as of December 31, 2023. The preliminary estimate of cash and cash equivalents reflect management's current views and may change as a result of management's review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of Barinthus Bio (which have yet to be performed) and should not be viewed as a substitute for full audited financial statements prepared in accordance with U.S. GAAP. In the course of preparing and finalizing the financial statements for the year ended December 31, 2023, the preliminary estimates of cash and cash equivalents for the year ended December 31, 2023 will be subject to change and Barinthus Bio may identify items that will require it to make adjustments to its preliminary estimates of its cash and cash equivalents. Any such changes could be material. For these or other reasons, the preliminary estimates of Barinthus Bio's cash and cash equivalents for the year ended December 31, 2023 may not ultimately be indicative of its results for such period and actual results may differ materially. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary estimated results, nor have they expressed any opinion or any other form of assurance on these preliminary estimated results.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 5, 2024, the Company issued a press release titled "Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Objectives." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Items 2.02 and 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words "expect," "will," and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding the Company's preliminary estimated cash and cash equivalents. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, risks and uncertainties related to the Company's preliminary estimates of its cash and cash equivalents, including the risk that final financial results may differ materially from the Company's preliminary estimates, and other risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated January 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Barinthus Biotherapeutics plc Date: January 5, 2024 By: /s/ William Enright William Enright Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR